GlassScriptPhysician profile
Victoria Pham
NPI 1104406073
$3,646.56
in general payments reported to CMS, 2019-2025
28 companies · $79.34 in 2025
The $79.34 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $650 · 2022: $939 · 2023: $1,014 · 2024: $964 · 2025: $79.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $991.93 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $752.11 | 2021-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $614.17 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $336.92 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $146.71 | 2021-2024 | Emgality, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $144.70 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $112.66 | 2021-2023 | |
| Astellas Pharma US INC | $42.68 | 2021-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.84 | 2021-2024 | Xifaxan |
| Medtronic, INC. | $38.23 | 2023 | Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.78 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $35.56 | 2024-2025 | Zoryve |
| Biohaven Pharmaceutical Holding Company LTD. | $34.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.09 | 2021-2022 | |
| Pfizer INC. | $30.86 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $28.23 | 2021-2022 | |
| Lundbeck LLC | $26.82 | 2023 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $25.36 | 2021 | |
| Axsome Therapeutics, INC. | $22.78 | 2024 | Auvelity |
| Cranial Technologies, INC | $21.45 | 2022 | |
| Shield Therapeutics INC | $20.51 | 2023 | Accrufer |
| Azurity Pharmaceuticals, INC. | $20.19 | 2024 | Edarbi |
| Paratek Pharmaceuticals, INC. | $17.38 | 2024 | Nuzyra |
| Currax Pharmaceuticals LLC | $17.18 | 2024 | Onzetra Xsail, Contrave |
| Merck Sharp & Dohme LLC | $15.16 | 2021 | |
| Sumitomo Pharma America, INC. | $14.84 | 2024 | Gemtesa |
| Exact Sciences Corporation | $13.80 | 2023 | Cologuard Collection Kit |
| Myovant Sciences INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.